Homes
Public Notices
News
Local news
Editor’s Pick
Pittsburgh
Local Government
Roads, Travel and Traffic
20 Years of Gas Drilling
Regional
U.S. and World
Business
Sports
HS Sports
College Sports
Penguins
Pirates
Steelers
Athlete of the Week
Wild Things
Pony Baseball
Outdoors
Columns
Opinion
Columns
Editorials
Letters to the Editor
Op Eds
Living
Neighbors
School News
Entertainment
Home and Garden
Food
Police Beat
Obituaries
Classifieds
Legal Notices
Sponsored Content
e-Edition
close
Washington County
Greene County
Mon Valley
News
Local news
Police Beat
Pittsburgh
Local Government
Roads, Travel and Traffic
Helping The Helpers
20 Years of Gas Drilling
Regional
U.S. and World
Business News
Sports
High School Sports
College Sports
Penguins
Pirates
Steelers
Wild Things
Pro Sports
Outdoors
Sports Column
Obituaries
Opinion
Columns
Editorials
Letters to the Editor
Op-Ed
Living
Neighbors
Health and Wellness
Entertainment
Home and Garden
Classifieds
Contact Us
Advertise With Us
Customer Service
Contact Information
Submission Forms
Statement of Values
Misc
Special Sections
Events
Sponsored Content
Newsletter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
GSK plc American Depositary Shares (Each representing two Ordinary Shares)
(NY:
GSK
)
58.93
+0.39 (+0.67%)
Official Closing Price
Updated: 7:00 PM EST, Feb 13, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about GSK plc American Depositary Shares (Each representing two Ordinary Shares)
< Previous
1
2
...
8
9
10
11
12
13
14
15
16
...
44
45
Next >
US FDA expands Jemperli (dostarlimab-gxly) plus chemotherapy approval to all adult patients with primary advanced or recurrent endometrial cancer as the first and only immuno-oncology-based treatment to show an overall survival benefit
August 01, 2024
From
GSK plc
Via
Business Wire
British Pharma Giant GSK's Blockbuster Shingles And Respiratory Syncytial Virus Vaccine Q2 Sales Miss Expectations, Cuts Annual Vaccine Revenue Guidance
↗
July 31, 2024
GSK reported Q2 sales of $9.95 billion, beating estimates of $9.66 billion. Specialty Medicine sales rose 20%, driven by strong HIV, Respiratory/Immunology, and Oncology performance. Core EPS of $1.10...
Via
Benzinga
Topics
Earnings
GSK Beats Second-Quarter Views, Raises Outlook; But Shares Fall On Shingrix Miss
↗
July 31, 2024
The company, however, raised its sales and earnings outlook for the year.
Via
Investor's Business Daily
GSK Stock Earnings: GSK Beats EPS, Beats Revenue for Q2 2024
↗
July 31, 2024
GSK stock results show that GSK beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via
InvestorPlace
Apple, Amazon, Microsoft, Meta Lead The Charge As Investors Bank On Tech Cheer For Rally's Reacceleration: Week Ahead In Earnings
↗
July 29, 2024
The unfolding week's market trajectory depends on earnings from bellwether tech stocks and what the Fed has to say following its July meeting.
Via
Benzinga
Topics
Economy
Is GSK a Top-Value Stock Right Now?
↗
July 17, 2024
GSK, a multinational pharma company, scans as a bargain.
Via
The Motley Fool
Tech Stocks On Track For Best Session In 5 Months Ahead Of Fed Meeting; Small Caps Target Highest Close Since January 2022: What's Driving Markets Wednesday?
↗
July 31, 2024
Tech stocks soared to their best session in five months on Wednesday, ahead of the highly anticipated Federal Open Market Committee (FOMC) meeting.
Via
Benzinga
Topics
Economy
GSK's Top Selling Vaccine Can Potentially Reduce Dementia Risk, Research Suggests
↗
July 26, 2024
New research suggests that GSK's Shingrix vaccine may reduce dementia risk, potentially revolutionizing treatment for older adults. The study, involving 200,000 people, indicates a significant...
Via
Benzinga
Wall Street Remains On Track For AMD-Led Rebound Ahead Of Fed Decision, Meta Earnings: Analyst Says 'The Bull Tends To Remain' Despite Near-Time Volatility
↗
July 31, 2024
Tech optimism is likely to abound on Wall Street as AI-levered stocks are feeding off the strength generated by Advanced Micro Devices, Inc.‘s (NASDAQ:AMD)
Via
Benzinga
Topics
Economy
Pfizer And GSK's ViiV Healthcare's Two-Drug HIV Treatment Matches Gilead's Three-Drug Combo In Major Trial
↗
July 23, 2024
ViiV Healthcare's Dovato matches Gilead's Biktarvy in effectiveness for HIV treatment. The study reveals Dovato's benefit of less weight gain compared to Biktarvy, highlighting its efficacy and patient...
Via
Benzinga
3 Stocks Under $10 With the Potential for Massive Gains
↗
July 22, 2024
Discover the growth potential of top small-cap stocks in the consumer finance, healthcare equipment and pharmaceutical industries.
Via
InvestorPlace
Top Research Reports For Apple, Lowe's & Shopify
↗
July 17, 2024
Today's Research Daily features new research reports on 16 major stocks, including Apple Inc., Lowe's Companies, Inc., and Shopify Inc., as well as two micro-cap stocks MIND Technology, Inc., and...
Via
Talk Markets
European Commission Faces Court Criticism Over COVID Vaccine Contract Transparency Ahead Of Vote on Ursula Von Der Leyen's Reappointment
↗
July 17, 2024
European Commission faces scrutiny over COVID vaccine contract transparency ahead of key vote. Legal challenges and implications discussed.
Via
Benzinga
3 Top Cancer Treatment Stocks to Buy Now
↗
July 17, 2024
These cancer treatment stocks are well-positioned to benefit tremendously from strong demand for their cancer treatments in the longer term.
Via
InvestorPlace
Positive News is Driving This Cancer Drug Maker’s Stock Higher
July 15, 2024
IDEAYA Biosciences stock is up more than 16% on positive treatment data in a Phase 2 clinical trial, but after a 76% run-up, IDYA stock may need a breather
Via
MarketBeat
The 3 Most Undervalued Pharma Stocks to Buy in July 2024
↗
July 12, 2024
Pharma stocks can be great investments during times of growth and recession, and are made even better if the stock is undervalued.
Via
InvestorPlace
Topics
Economy
GSK Begins Shipping Influenza Vaccine Doses for 2024-25 Season
July 11, 2024
From
GSK plc
Via
Business Wire
3 Dirt-Cheap Drug Developers With Blockbuster Potential
↗
July 11, 2024
These are three of the best cheap drug developer stocks for investors to keep an eye as their growth could be imminent.
Via
InvestorPlace
Health Officials Keep Close Eye On Bird Flu As It Infects Cows For The First Time
↗
July 10, 2024
Avian influenza continues to spread among animals and has infected four dairy workers in the US. Concerns about human-to-human transmission are low.
Via
Benzinga
The 3 Most Undervalued Under-$50 Stocks to Buy in July 2024
↗
July 09, 2024
A full-throated bull market makes it tough to find undervalued stocks under $50, but these three could soon lead the charge higher.
Via
InvestorPlace
Pfizer's RSV Vaccine Abrysvo Clears Concerns Over Preterm Birth Risk, Safety For Pregnant Women, New Study Shows
↗
July 08, 2024
Pfizer's RSV vaccine, Abrysvo, for pregnant women shows no increased risk of pre-term births, according to a study. Researchers found no significant difference in pre-term birth rates between...
Via
Benzinga
United Kingdom Stocks, ETFs To Watch After Keir Starmer, Labour Party Win
↗
July 05, 2024
New leadership in the United Kingdom could make several sectors standout going forward. Here's what experts are saying after the election.
Via
Benzinga
Topics
ETFs
Upcoming Stock Spinoffs: Should You Pounce or Pass?
↗
July 04, 2024
Stock spinoffs are a unique opportunity to pick up unloved, unwanted businesses but patience is often needed before buying in.
Via
InvestorPlace
CureVac Layoffs 2024: What to Know About the Latest CVAC Job Cuts
↗
July 03, 2024
CureVac layoffs are coming for 30% of the vaccine company's employees as it prepares for a restructuring that will save it over 30% in costs.
Via
InvestorPlace
Topics
Workforce
CVAC Stock Alert: CureVac Pops on Licensing Deal With GSK
↗
July 03, 2024
CureVac stock is up on Wednesday as CVAC investors react to the company signing a new 1.4 billion euro licensing agreement with GSK.
Via
InvestorPlace
GSK Buys Full Rights To Investigational Covid-19 And Influenza Vaccines From CureVac For Around $1.5B
↗
July 03, 2024
GSK and CureVac restructured their collaboration into a new licensing agreement, prioritizing mRNA vaccine development. GSK gains full control of vaccine candidates for influenza and COVID-19, while...
Via
Benzinga
3 No-Brainer Stocks to Buy With $300 Right Now for the Second Half of 2024
↗
July 03, 2024
A modest amount of money can go a long way when it's put to work in highly innovative, game-changing businesses.
Via
The Motley Fool
Heartburn Drug Zantac Litigation: GSK And Other Pharma Giants Face Trial Over Cancer Claims
↗
July 02, 2024
A Delaware judge dismissed GSK and other drugmakers' appeal, allowing over 70,000 lawsuits alleging Zantac causes cancer to proceed, with the companies needing Delaware Supreme Court approval to...
Via
Benzinga
Topics
Lawsuit
CDC Advisor Panel Recommends RSV Shots In US For People Above 75 Years, Analyst Says Decision Negative For GSK
↗
June 27, 2024
The CDC's ACIP recommends RSV vaccines for adults 75+, and for those 60-74 with chronic conditions. GSK's Arexvy is approved for adults 50-59 at risk. A decision on adults 50-59 is pending further...
Via
Benzinga
Why Is Moderna Stock Trading Lower On Wednesday?
↗
June 26, 2024
The CDC's Advisory Committee on Immunization Practices is set to discuss recommendations for RSV, influenza, and COVID-19 vaccines. Moderna's data shows vaccine efficacy drops to 50% after 18 months in...
Via
Benzinga
< Previous
1
2
...
8
9
10
11
12
13
14
15
16
...
44
45
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
Starting at $3.75
/
week.
Subscribe Today